BioPharma Dive October 28, 2024

Sponsored content By TriNetX

In June 2024, the U.S. Food and Drug Administration (FDA) issued draft guidance outlining the need for “Diversity Action Plans” as a way for clinical trial sponsors to demonstrate their consideration toward trial representation. Affecting phase 3 studies, and others as appropriate, the guidance iterates on a previous draft from 2022 borne from the Food and Drug Omnibus Reform Act (FDORA) that same year.

As sponsors plan their compliance with this near-final guidance, they’re likely to rethink their protocol development process more systemically—or at least, they should, experts say.

For the brands including big pharma that tend to work from libraries of global protocol templates with pre-established inclusion and exclusion criteria, the guidance will likely...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), EMR / EHR, Equity/SDOH, FDA, Govt Agencies, Health IT, Healthcare System, Patient / Consumer, Provider, Technology
Modest decline seen in portal messaging with billing implementation
Mayo Clinic patient portal messages dropped after e-visit billing
The Role of Patient-Generated Health Data and Wearable Technology in the Future Innovation of EHR Systems
Australia’s Digital Health Transformation: Black Book Research Reveals 2025 EHR Vendor Rankings and Insights
Why women doctors spend more time on EHRs and what it means for patient care

Share This Article